ERG and prostate carcinoma: A notable example is the E26 translationally specific (ETS) family of transcription factor fusions in prostate cancer (Kumar-Sinha et al., 2008), with the TMPRSS2-ERG fusion being the most prevalent, occurring in approximately 50% of prostate cancer cases (Tomlins et al., 2005).